Sellas Life Sciences Group Inc.

1 trials Commercial sponsor

Filter these 1 trials by condition, phase, country and more.

Open in Search →

1 Registered trials

0 Recruiting

1 Completed trials

5 Countries active

6 Unique IMPs

100% Results reported

Phase III

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

AZACITIDINE 1 CYTARABINE 1 DECITABINE 1 SARGRAMOSTIM 1 TYR-MET-PHE-PRO-ASN-ALA-PRO-TYR-LEU, SER-GLY-GLN-ALA-TYR-MET-PHE-PRO-ASN-ALA-PRO-TYR-LEU-PRO-SER-CYS-LEU-GLU-SER, ARG-SER-ASP-GLU-LEU-VAL-ARG-HIS-HIS-ASN-MET-HIS-GLN-ARG-ASN-MET-THR-LYS-LEU AND PRO-GLY-CYS-ASN-LYS-ARG-TYR-PHE-LYS-LEU-SER-HIS-LEU-GLN-MET-HIS-SER-ARG-LYS-HIS-THR-GLY 1 VENETOCLAX 1

All trials

1 total

A Study of the Efficacy and Safety of Galinpepimut-S (GPS) for the Treatment of Acute Myeloid Leukemia Compared to Investigator's Choice of … Ended

2024-516405-23-00 Phase III 5 countries AZACITIDINE; CYTARABINE; DECITABINE; SARGRAMOSTIM; TYR-MET-PHE-PRO-ASN-ALA-PRO-T…

Showing 1–1 of 1 trials

← All sponsors A–Z